Altimmune Inc (ALT): Price-to-Revenue Ratio

Corporate company logo of Altimmune Inc (ALT)

Altimmune, Inc. (ALT) focuses on bringing pemvidutide to market for the therapy of steatohepatitis and the fight against obesity. Peptide development allows for the reduction of adipose tissue while preserving muscle mass. The current price-to-sales ratio reflects market expectations, with the value fixed at 10376.90. The company is fighting for market share in the metabolism segment, utilizing the drug's unique mechanism of action to counter pressure from industry behemoths.

Altimmune (ALT): Price-to-Revenue Ratio from 07/04/2022 to 11/13/2026

Analytical breakdowns for Altimmune Corp (ALT)

- current quotes and average value forecast:
Market Price altimmune.com|ALT - Price Target Chart
- stock exchange capitalization data:
Market Value Altimmune Corp|ALT - Enterprise Value
- issuer book value statistics:
Net Assets per Share Altimmune|ALT - Company Book Value|Market Capitalization to Book Value altimmune.com|ALT - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Altimmune, Inc.|ALT - Long-Term Debt to Capital|Short-Term Debt to Capital Altimmune Pharma|ALT - Company Debts|Debt to Book Capitalization Ratio Altimmune Corp|ALT - Company Long-Term Liabilities|Amount of Current Liabilities Altimmune|Interim Coverage Ratio altimmune.com
- net income and valuation ratios data:
ALT - Company Net Income|Future Profit Altimmune, Inc.|ALT - Price to Earnings Ratio|Projected Price to Earnings Altimmune Inc|ALT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Altimmune Corp|ALT - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Altimmune|ALT - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months altimmune.com|ALT - Net earnings per share growth this year|Expected earnings per share trend next year Altimmune, Inc.
- total revenue and sales volume data:
ALT - Revenue and Sales Volume|Company Future Sales altimmune.com|ALT - Price-to-Revenue Ratio|Market Cap to Projected Revenue Altimmune Corp
Fundamental company analysis:altimmune.com ALT
Original product of Altimmune Corp

The P/S multiple determines the market value of one dollar of revenue, allowing an investor to assess the degree of overpayment for a business relative to its actual sales. By analyzing the ratio of market capitalization to revenue, one can correlate market expectations with the efficiency of obesity drug development and the optimization of component logistics, which provides Altimmune, Inc. (ALT) with high operating profitability.

Who Altimmune, Inc. competes with

ASND - Price to Sales|Price-to-Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. - Price-to-Revenue Ratio|Rhythm Pharmaceuticals Inc - P/S Multiple|Price-to-Revenue Coefficient Akero Corp AKRO|Metsera Inc (MTSR) - Price-to-Revenue Ratio|MLTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Crinetics|Market Cap to Revenue NewAmsterdam Pharma Company (NAMS)|P/S Multiple SLNO|P/S Multiple Amicus Corp (FOLD)|Price-to-Revenue Ratio 89bio, Inc. ETNB|agios.com - Price-to-Revenue Ratio|GPCR: Market Cap to Revenue|MiMedx Group Inc - Market Cap to Sales Volume|RZLT: P/S Multiple|LXRX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio MBX Biosciences Inc|Market Cap to Revenue aardvarktherapeutics.com (AARD)|Price-to-Revenue Ratio Sagimet Biosciences Inc. (SGMT)|Market Cap to Revenue BioAge Labs BIOA|Biomea - Market Cap to Revenue|P/S Multiple Quince Therapeutics Inc QNCX|GUTS - Price-to-Revenue Ratio|VTVT (vTv Therapeutics Inc.) - Market Cap to Revenue Ratio|ATPC: P/S Multiple|Price to Sales Pluri (PLUR)|Market Cap to Revenue SYBX|LPCN: Market Capitalization-to-Revenue Ratio|P/S Multiple MTNB|Price-to-Revenue Coefficient sprucebiosciences.com|Price-to-Revenue Ratio Galecto GLTO|CTCX: Market Cap to Revenue Ratio|Lumos Pharma Corp - P/S Multiple|Organovo Corp (ONVO) - Market Cap to Revenue|RDUS (Radius Recycling, Inc.) - Market Cap to Revenue